Encompass Health (NYSE:EHC) has received mixed analyst ratings over the past three months, with 6 analysts offering evaluations. The sentiment has shifted slightly positive, with the average 12-month price target rising to $88.67 from $84.67. Analysts from Barclays, Truist Securities, RBC Capital, Mizuho, and Stephens & Co. have provided updates, with actions including raising and maintaining ratings, and adjusting price targets. Encompass Health's financial performance shows strong market position, revenue growth, profitability, and effective asset utilization, despite facing challenges in achieving growth rates higher than the average in the Health Care sector.